JY
TSHA icon

Jeff Yass’s Taysha Gene Therapies TSHA Stock Holding History

Jeff Yass’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8M Buy
558,000
+440,300
+374% +$2.61M ﹤0.01% 5146
2026
Q1 		$526K Buy
117,700
+60,500
+106% +$281K ﹤0.01% 9539
2025
Q4 		$315K Sell
57,200
-4,600
-7% -$22.3K ﹤0.01% 9834
2025
Q3 		$202K Sell
61,800
-31,500
-34% -$89.2K ﹤0.01% 10967
2025
Q2 		$216K Buy
93,300
+28,800
+45% +$62.6K ﹤0.01% 11060
2025
Q1 		$89.7K Buy
64,500
+18,300
+40% +$30.6K ﹤0.01% 11605
2024
Q4 		$79.9K Buy
46,200
+30,700
+198% +$63.7K ﹤0.01% 11470
2024
Q3 		$31.2K Sell
15,500
-34,000
-69% -$74.6K ﹤0.01% 11528
2024
Q2 		$111K Buy
49,500
+22,000
+80% +$64K ﹤0.01% 10951
2024
Q1 		$78.9K Sell
27,500
-7,600
-22% -$15.8K ﹤0.01% 11345
2023
Q4 		$62.1K Sell
35,100
-50,200
-59% -$100K ﹤0.01% 11619
2023
Q3 		$270K Buy
+85,300
New +$159K ﹤0.01% 9589
2022
Q4 		– Sell
-15,600
Closed -$30K – 13702
2022
Q3 		$30K Buy
+15,600
New +$56.6K ﹤0.01% 12448

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's TSHA Position: Q2 2026 in Review

Jeff Yass reduced its Taysha Gene Therapies (TSHA) stake by 77% in Q2 2026, selling an estimated $527K and leaving 27,164 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #12036.

Jeff Yass first reported a position in TSHA in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.76M in Q1 2024. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Jeff Yass held 27,164 shares of Taysha Gene Therapies worth $185K as of Q2 2026.
  • Jeff Yass sold 89,133 Taysha Gene Therapies shares in Q2 2026, an estimated $527K.
  • Taysha Gene Therapies made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12036 holding.
  • Jeff Yass first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 15 quarters since.
  • Jeff Yass's Taysha Gene Therapies position peaked at $3.76M in Q1 2024.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.